• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

    5/16/24 10:26:17 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRTX alert in real time by email
    SC 13G/A 1 ea0206277-13ga2schneid_gale.htm AMENDMENT NO. 2 TO FORM SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 2)

     

    GALERA THERAPEUTICS INC.

     

    (Name of Issuer)

     

    COMMON STOCK

     

    (Title of Class of Securities)

     

    36338D108

     

    (CUSIP Number)

     

    April 16, 2024

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following page(s)

     

     

     

    Page 1 of 5 Pages

     

    CUSIP No. 36338D108 13G/A Page 2 of 5 Pages

     

    1.

    NAMES OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  

     

    Yair Schneid

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: 

    (a) ☐

    (b) ☐

    3.

    SEC USE ONLY  

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    5. SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      10,823,610 Shares (1)(2)
    6. SHARED VOTING POWER
       
      None
    7. SOLE DISPOSITIVE POWER
       
      10,823,610 Shares (1)(2)
    8. SHARED DISPOSITIVE POWER
       
      None
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      10,823,610 Shares (1)(2)
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
       
      [   ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
       
      19.90% (1)(2)
    12. TYPE OF REPORTING PERSON
       
      IN

     

    (1)Based on 54,392,170 shares outstanding as of March 28, 2024 as reported on Form 10-K for the period ended December 31, 2023 filed with the Securities and Exchange Commission on March 28, 2024.
      
    (2)Does not include 3,178,137 shares of common stock held by Rochel Soffer individually and 2,750,000 shares of common stock held by Alpha Pharma Investments LLC. Rochel Soffer is the spouse of the Reporting Person and is also the sole member of Alpha Pharma Investments LLC. Rochel Soffer has voting and dispositive power of Alpha Pharma Investments LLC and is therefore deemed the beneficial owner of such securities. The Reporting Person disclaims beneficial ownership of all securities owned by Rochel Soffer and Alpha Pharma Investments LLC, except to the extent of their pecuniary interest therein, if any.

     

     

     

    CUSIP No. 36338D108 13G/A Page 3 of 5 Pages

     

    ITEM 1(a) NAME OF ISSUER: Galera Therapeutics Inc.

     

    ITEM 1(b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    45 Liberty Blvd., Suite 230, Malvern, Pennsylvania 19355

     

    ITEM 2(a) NAME OF PERSON FILING: Yair Schneid

     

    ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    1 Wood Lane, Suffern, NY 10901

     

    ITEM 2(c) CITIZENSHIP: USA

     

    ITEM 2(d) TITLE OF CLASS OF SECURITIES: Common Shares, $0.001 par value per share

     

    ITEM 2(e) CUSIP NUMBER: 36338D108

     

    ITEM 3IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 10,823,610 Shares (1)(2)

     

    (b) PERCENT OF CLASS: 19.90% (1)(2)

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    10,823,610 Shares (1)(2)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    10,823,610 Shares (1)(2)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

    CUSIP No. 36338D108 13G/A Page 4 of 5 Pages

     

    ITEM 5OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

    CUSIP No. 36338D108 13G/A Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      May 15, 2024
      (Date)
       
      /s/ Yair Schneid
      (Signature)
       
      Yair Schneid
      (Name/Title)

     

     

     

     

     

    Get the next $GRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$6.00 → $0.50Overweight → Neutral
    Piper Sandler
    12/20/2021$11.00 → $20.00Buy
    Citigroup
    12/15/2021$10.00Neutral → Buy
    HC Wainwright & Co.
    12/15/2021$15.00Neutral → Buy
    BTIG
    10/20/2021Buy → Neutral
    HC Wainwright & Co.
    10/19/2021$17.00 → $2.00Buy → Underperform
    BofA Securities
    10/19/2021Buy → Neutral
    BTIG Research
    More analyst ratings

    $GRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chang Nancy T bought $499,979 worth of shares (7,644,932 units at $0.07) (SEC Form 4)

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      1/2/25 4:12:36 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schneid Yair bought $590,424 worth of shares (2,780,407 units at $0.21), increasing direct ownership by 35% to 10,823,610 units (SEC Form 4) (Amendment)

      4/A - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/1/24 5:02:03 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schneid Yair bought $166,417 worth of shares (932,402 units at $0.18), increasing direct ownership by 13% to 8,043,203 units (SEC Form 4)

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      2/26/24 4:06:04 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

      SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/16/24 10:26:17 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galera Therapeutics Inc.

      SC 13G - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/16/24 10:25:53 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

      SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/1/24 5:01:34 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galera Therapeutics completes acquisition of Nova Pharmaceuticals

      Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer. Concurrent financing when added to Galera's existing cash balance, is anticipated to fund operations through data readout of its lead program and into 2026. Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective clinical dataset expansion. MALVERN, Pa.

      12/31/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Announces Board Approval of Complete Liquidation and Dissolution

      MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024. If the Plan of Dissolution is approved by the Company's stockholders, the Company intends t

      8/14/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

      MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. "Our review of strategic options continues, as we strive to maximize value for our stockholders," said Mel Sorensen, M.D., Galera's President and CEO. "Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path

      5/13/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Leadership Updates

    Live Leadership Updates

    See more

    $GRTX
    SEC Filings

    See more
    • Galera Expands Commercial Leadership Team

      Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application (NDA) for avasopasem is currently under priority review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee (PDUFA) target date of August 9, 2023 MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of accomplished pharmace

      5/1/23 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer

      MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (CMO). Dr. Kennedy is a renowned Johns Hopkins-trained surgical oncologist and former Chief of Pancreatic and Hepatobiliary Surgery at Thomas Jefferson University with over 15 years' experience in clinical development and biopharma leadership. He will succeed Jon T. Holmlund, M.D., who will retire at the end of this yea

      9/1/22 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer

      MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer (CCO) and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer (CLCO) and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry. "We are thrilled to welcome Mark and Jennifer to Galera at this critical point in the Company's growth," sa

      10/12/21 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Galera Therapeutics Inc.

      8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

      4/2/25 5:05:17 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Galera Therapeutics Inc.

      10-K - Galera Therapeutics, Inc. (0001563577) (Filer)

      3/31/25 4:30:34 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Galera Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K/A - Galera Therapeutics, Inc. (0001563577) (Filer)

      3/24/25 6:13:44 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Financials

    Live finance-specific insights

    See more
    • Galera Therapeutics completes acquisition of Nova Pharmaceuticals

      Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer. Concurrent financing when added to Galera's existing cash balance, is anticipated to fund operations through data readout of its lead program and into 2026. Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective clinical dataset expansion. MALVERN, Pa.

      12/31/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Adopts Limited Duration Stockholder Rights Agreement

      MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the "Board") has unanimously resolved to adopt a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in the comp

      5/3/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

      The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and continue enrolling its rucosopasem clinical trials Conference call tomorrow, August 10, 2023 at 8:30 a.m. ET MALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food an

      8/9/23 4:31:52 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galera downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Galera from Overweight to Neutral and set a new price target of $0.50 from $6.00 previously

      8/10/23 7:27:44 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Galera Therapeutics with a new price target

      Citigroup reiterated coverage of Galera Therapeutics with a rating of Buy and set a new price target of $20.00 from $11.00 previously

      12/20/21 9:46:24 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Galera Therapeutics from Neutral to Buy and set a new price target of $10.00

      12/15/21 6:42:14 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Sussman Joel F.

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/5/25 4:19:43 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Sorensen Mel

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/5/25 4:17:46 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lokay Kevin G

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      2/26/25 4:57:11 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care